Charles River Laboratories International, Inc. CRL
342.69 USD -3.11 (-0.90%)
At closeNov 12, 2026, 8:53 AM EST
340.00 -2.69 -0.78%
Pre-market · Nov 12, 8:53 AM ET
342.25 Day range 356.00
146.20 52-week range 379.63
- YTD
- +71.79%
- 1 year
- +97.52%
News
defenseworld.net 5,106 Charles River Laboratories International, Inc. $CRL Shares Purchased by Brighton Jones LLC Brighton Jones LLC increased its holdings in shares of Charles River Laboratories International, Inc. (NYSE: CRL) by 546.1% during the undefined quarter, according to its most recent Form 13F filing…
benzinga.com Charles River Laboratories Recent $470 Million Deal an 'Attractive Strategic Addition,' Analyst Says Charles River Laboratories will buy Frontage's bioanalysis unit for $470 million in cash to expand its clinical drug testing scale.
prnewswire.com Tigermed to Participate in the Privatization of Frontage Holdings Corporation and Divest Its Overseas Laboratory Services Business HANGZHOU, China, Nov. 10, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. (Stock Codes: 300347.SZ / 3347.HK, hereinafter referred to as "Tigermed"), a leading global provider of…
zacks.com Here's Why Charles River Laboratories (CRL) is a Strong Momentum Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
zacks.com Unlocking Charles River (CRL) International Revenues: Trends, Surprises, and Prospects Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
benzinga.com Charles River Laboratories To Acquire Frontage Holdings Corporation’s Bioanalysis And DMPK Operations In Pennsylvania For ~$470M In Cash Plus Additional Payments Of Up To $75M The transaction is expected to close during the first half of 2027, subject to required shareholder and regulatory approvals, and other customary closing conditions. Frontage’s laboratory testing…
businesswire.com Charles River Laboratories to Acquire Frontage's Bioanalysis and DMPK Businesses WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Acquire Frontage's Bioanalysis and DMPK Businesses.
benzinga.com UBS Maintains Buy on Charles River, Raises Price Target to $387 UBS analyst Kevin Caliendo maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $357 to $387.
benzinga.com RBC Capital Maintains Outperform on Charles River, Raises Price Target to $352 RBC Capital analyst Ryan Halsted maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $322 to $352.
benzinga.com Barclays Maintains Overweight on Charles River, Raises Price Target to $375 Barclays analyst Luke Sergott maintains Charles River (NYSE:CRL) with a Overweight and raises the price target from $330 to $375.
benzinga.com Evercore ISI Group Maintains Outperform on Charles River, Raises Price Target to $400 Evercore ISI Group analyst Ross Muken maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $330 to $400.
marketbeat.com Charles River Laboratories International Q3 Earnings Call Highlights Charles River Laboratories International NYSE: CRL raised its 2026 revenue and earnings outlook after third-quarter organic revenue growth accelerated to 4.7%, supported by demand for safety…
defenseworld.net Boston Trust Walden Corp Sells 37,537 Shares of Charles River Laboratories International, Inc. $CRL Boston Trust Walden Corp reduced its stake in Charles River Laboratories International, Inc. (NYSE: CRL) by 13.0% during the undefined quarter, according to its most recent 13F filing with the…
benzinga.com Charles River Q3 2026 Earnings Call Transcript Charles River (NYSE:CRL) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you…- benzinga.com Charles River Widens FY2026 Adj EPS Guidance from $11.45 to $11.35-$11.55 vs $11.38 Est; Raises FY2026 Sales Guidance from $3.915B to $3.940B-$3.960B vs $3.916B Est Charles River (NYSE:CRL) widens FY2026 Adj EPS guidance from $11.45 to $11.35-$11.55 vs $11.38 analyst estimate. Raises FY2026 sales outlook from $3.915 billion to $3.940 billion-$3.960 billion vs…
benzinga.com Charles River Laboratories' Virtual Control Group Database And Methodology To Be Used In An Upcoming Good Laboratory Practice-Compliant Study For Ipsen This collaboration highlights Charles River’s and Ipsen’s dedication and commitment to championing the 3Rs (Replacement, Reduction, and Refinement of animal use in research) while upholding the…- benzinga.com Charles River Laboratories Announces Research Collaboration Agreement With FDA And Labcorp For Developing Sensitive Screening Tools To Quantify And Rank Abuse Potential Of New Drugs Joint research effort seeks to improve abuse potential assessment tools to support drug development and public health decision-makingCharles River Laboratories International, Inc. (NYSE:CRL) today…
benzinga.com $1000 Invested In Charles River 15 Years Ago Would Be Worth This Much Today Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 4.33% on an annualized basis producing an average annual return of 17.1%. Currently, Charles River has a market…
benzinga.com SpaceX Jumps 10%, Nasdaq 100 Rises as AI Trade Returns: Stock Market Today SpaceX's blowout third quarter and Super Micro's guidance hike revive the AI trade, lifting the Nasdaq 100 as Netflix and AT&T slide on results.
benzinga.com Here’s How Much You Would Have Made Owning Charles River Stock In The Last 20 Years Charles River (NYSE:CRL) has outperformed the market over the past 20 years by 1.14% on an annualized basis producing an average annual return of 10.15%. Currently, Charles River has a market…
benzinga.com Morgan Stanley Maintains Overweight on Charles River, Raises Price Target to $340 Morgan Stanley analyst Ricky Goldwasser maintains Charles River (NYSE:CRL) with a Overweight and raises the price target from $300 to $340.- benzinga.com Charles River Laboratories International Partners With Magellan Stem Cells For Development, Clinical Advancement Of Stem Cell-Based Therapies, Regenerative Medicine Solutions Charles River Laboratories International, Inc. (NYSE: CRL) and Magellan Stem Cells, a private Australian biotech and cell-therapy firm, announce their collaboration to support Magellan in the…
- benzinga.com Charles River Laboratories and Autolomous Launch Apollo Orchestrate To Digitize Laboratory Execution Through autoloMATE Integration Partnership reinforces continued investment in digitization, automation, and client-facing transparencyCharles River Laboratories International, Inc. (NYSE:CRL) and Autolomous today announced the…
- benzinga.com Here's How Much $1000 Invested In Charles River 15 Years Ago Would Be Worth Today Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 3.32% on an annualized basis producing an average annual return of 16.72%. Currently, Charles River has a market…
- benzinga.com Jefferies Maintains Buy on Charles River, Raises Price Target to $340 Jefferies analyst David Windley maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $305 to $340.
- benzinga.com Deutsche Bank Maintains Buy on Charles River, Raises Price Target to $320 Deutsche Bank analyst Justin Bowers maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $300 to $320.
benzinga.com TD Cowen Maintains Buy on Charles River, Raises Price Target to $325 TD Cowen analyst Charles Rhyee maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $300 to $325.- benzinga.com Evercore ISI Group Maintains Outperform on Charles River, Raises Price Target to $330 Evercore ISI Group analyst Ross Muken maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $320 to $330.
benzinga.com RBC Capital Maintains Outperform on Charles River, Raises Price Target to $322 RBC Capital analyst Ryan Halsted maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $282 to $322.- benzinga.com Barclays Maintains Overweight on Charles River, Raises Price Target to $330 Barclays analyst Luke Sergott maintains Charles River (NYSE:CRL) with a Overweight and raises the price target from $300 to $330.
- benzinga.com Mizuho Maintains Neutral on Charles River, Raises Price Target to $295 Mizuho analyst Ann Hynes maintains Charles River (NYSE:CRL) with a Neutral and raises the price target from $264 to $295.
benzinga.com Baird Maintains Outperform on Charles River, Raises Price Target to $334 Baird analyst Eric Coldwell maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $291 to $334.
benzinga.com S&P 500 Erases Losses as US, Iran Reportedly Discuss Hormuz Deal: Stock Market Today Stocks pared a sharp morning selloff after sources said US and Iranian negotiators are discussing a phased deal to reopen the Strait of Hormuz.
benzinga.com Everpure, Fervo Energy, Charles River Laboratories And Other Big Stocks Moving Higher On Thursday Nasdaq fell 150+ points, while Everpure jumped 14% after unveiling growth plans and a FY2028 outlook; other stocks also gained.- benzinga.com Charles River Laboratories International Reiterates FY26 Revenue, Non-GAAP Earnings Outlook, Expects FY30 Organic Revenue Growth In Range Of 5% To 7% Charles River Laboratories International, Inc. (NYSE: CRL) will host its 2026 Investor Day today, September 24, 2026, starting at 9:00 a.m. ET.The Company is also introducing the following long-term…
- benzinga.com Here's How Much $1000 Invested In Charles River 15 Years Ago Would Be Worth Today Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 2.57% on an annualized basis producing an average annual return of 15.86%. Currently, Charles River has a market…
- benzinga.com Evercore ISI Group Maintains Outperform on Charles River, Raises Price Target to $320 Evercore ISI Group analyst Ross Muken maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $300 to $320.
benzinga.com This SpaceX Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday Wall Street analysts upgraded AVITA, Etsy, Unity, and raised target prices for these stocks. See what others think before buying Unity.
benzinga.com This Danaos Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday Wall Street analysts change outlook on top names. See all rating changes, upgrades, downgrades and initiations at Benzinga's analyst ratings page.
benzinga.com Gold Jumps 4%, Dow Jones Smashes Record Highs: Stock Market Today Gold posts its biggest one-day gain since February and the Dow sets a record as Iran deal hopes cool inflation fears.
benzinga.com Wynn Resorts Posts Upbeat Q2 Earnings, Joins Bloomin' Brands, Shopify, Owens Corning And Other Big Stocks Moving Higher On Wednesday US stocks rise, Wynn Resorts beat earnings expectations, share price jumps 10.9%. Other companies recording gains in today's session.
benzinga.com Sherwin-Williams Posts Upbeat Q2 Earnings, Joins Itron, Armstrong World And Other Big Stocks Moving Higher On Tuesday U.S. stocks mixed, Dow Jones up 300 points. Shares of Sherwin-Williams rose 7.8% after reporting better-than-expected earnings and raising FY26 guidance.
benzinga.com Keysight To Rally Over 24%? Here Are 10 Top Analyst Forecasts For Monday Wall Street analysts change outlook on top names. Complete view of analyst rating changes including upgrades/downgrades. See analyst ratings page.
benzinga.com This Charles River Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday Top Wall Street analysts upgraded MITT & MFA. See ratings & price targets for these stocks. Should you buy MFA?- benzinga.com Delta Air Lines To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Wednesday Top Wall Street analysts changed outlook on top names. Baird raised prices for Ryder System and J B Hunt, Needham for Glaukos, B of A for CSX, Morgan Stanley for Charles River, and Bernstein for…
benzinga.com 10 Health Care Stocks With Whale Alerts In Today's Session 
benzinga.com Earnings Scheduled For February 18, 2026 
benzinga.com This Charles River Laboratories Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday 
benzinga.com Robinhood To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Thursday 
benzinga.com Earnings Scheduled For November 5, 2025